Evotec 566480, wohin geht die Reise??? (Seite 6256)
eröffnet am 12.01.07 11:23:52 von
neuester Beitrag 11.05.24 11:52:35 von
neuester Beitrag 11.05.24 11:52:35 von
Beiträge: 82.084
ID: 1.104.790
ID: 1.104.790
Aufrufe heute: 159
Gesamt: 16.241.378
Gesamt: 16.241.378
Aktive User: 0
ISIN: DE0005664809 · WKN: 566480
9,5425
EUR
0,00 %
0,0000 EUR
Letzter Kurs 12.05.24 Lang & Schwarz
Neuigkeiten
| Evotec Aktien jetzt im kostenlosen Demokonto handeln!Anzeige |
12.05.24 · wO Chartvergleich |
11.05.24 · wO Chartvergleich |
10.05.24 · Shareribs Anzeige |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,8800 | +57,45 | |
| 17,440 | +44,61 | |
| 1,8400 | +26,03 | |
| 4,9500 | +25,32 | |
| 4,0000 | +25,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,965 | -18,48 | |
| 0,7845 | -19,36 | |
| 3,3200 | -22,61 | |
| 0,6785 | -26,19 | |
| 3,3100 | -77,44 |
Beitrag zu dieser Diskussion schreiben
Feedback
Hier mal in kleiner Artikel zu einer kürzlichen Patentanmeldung seitens Develogen. Mglw. können unsere Biotech Experten dies in irgend einer Form bewerten/kommentieren:
DeveloGen Aktiengesellschaft; Agency Reviews Patent Application Approval Request for "New Formulation for Increasing Bioavailability of Neurturin"
1532 words
22 March 2013
Health & Medicine Week
HAMW
1442
English
(c) Copyright 2013 Health & Medicine Week via NewsRx.com
2013 MAR 22 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- DeveloGen Aktiengesellschaft has been issued patent application serial number 595706, according to news reporting originating out of Washington, D.C., by NewsRx editors.
The patent's inventors are Harder, Friedrich (Wasserburg, DE); Austen, Matthias (Gottingen, DE).
This patent application was filed on August 27, 2012 and was cleared for further review on March 7, 2013.
From the background information supplied by the inventors, news correspondents obtained the following quote: "Pancreatic beta-cells secrete insulin in response to elevated blood glucose levels. Insulin amongst other hormones plays a key role in the regulation of the fuel metabolism. Insulin leads to the storage of glycogen and triglycerides and to the synthesis of proteins. The entry of glucose into muscles and adipose cells is stimulated by insulin. In patients who suffer from diabetes mellitus type I or LADA (latent autoimmune diabetes in adults, Pozzilli & Di Mario, 2001, Diabetes Care. 8:1460-1467) beta-cells are being destroyed due to autoimmune attack. The amount of insulin produced by the remaining pancreatic islet cells is too low, resulting in elevated blood glucose levels (hyperglycemia). In diabetes mellitus type II liver and muscle cells loose their ability to respond to normal blood insulin levels (insulin resistance). High blood glucose levels (and also high blood lipid levels) in turn lead to an impairment of beta-cell function and to an increase in beta-cell death. Interestingly the rate of beta-cell neogenesis and replication does not appear to increase in type II diabetics, thus causing a reduction in total beta-cell mass over time. Eventually the application of exogenous insulin becomes necessary in type II diabetics.
"In type I diabetics, where beta-cells are being destroyed by autoimmune attack, treatments have been devised which modulate the immune system and may be able to stop or strongly reduce islet destruction (Raz et al., 2001, Lancet 358: 1749-1753; Chatenoud et al., 2003, Nat Rev Immunol. 3: 123-132; Homann et al., Immunity. 2002, 3:403-415). However, due to the relatively slow regeneration of human beta-cells such treatments can be more successful if they are combined with treatments that can stimulate beta-cell regeneration.
"Diabetes is a very disabling disease, because today's common anti-diabetic drugs do not control blood sugar levels well enough to completely prevent the occurrence of high and low blood sugar levels. Frequently elevated blood sugar levels are toxic and cause long-term complications like for example nephropathy; retinopathy, neuropathy and peripheral vascular disease. Extensive loss of beta cells also leads to deregulation of glucagon secretion from pancreatic alpha cells which contributes to an increased risk of dangerous hypoglycemic episodes. There is also a host of related conditions, such as obesity, hypertension, heart disease and hyperlipidemia, for which persons with diabetes are substantially at risk.
"Apart from the impaired quality of life for the patients, the treatment of diabetes and its long term complications presents an enormous financial burden to our healthcare systems with rising tendency. Thus, for the treatment of diabetes mellitus type I and LADA, but also for the treatment of late stages of diabetes mellitus type II there is a strong need in the art to identify factors that induce regeneration of pancreatic insulin producing beta-cells. These factors could restore normal function of the endocrine pancreas once its function is impaired or event could prevent the development or progression of diabetes type I, LADA or diabetes type II.
"Neurturin is expressed in embryonic pancreas, and recombinant neurturin has been shown to stimulate the differentiation of mouse ES-cells into insulin producing cells. Moreover, transgenic mice with elevated neurturin levels in the pancreas have a substantially increased pancreatic beta-cell mass. Based on these findings, the use of neurturin for the treatment of pancreatic disorders such as diabetes has been proposed (see for example WO03/099318 and WO2005/051415, the disclosure of which is herein incorporated by reference).
"Neurturin had previously been proposed as a treatment for neurodegenerative diseases such as Parkinsons, Alzheimers and Huntington's disease, motor neuron disorders, spinal cord injuries or hearing disorders (WO 97/08196, WO 99/06064; Akerud et al. J Neurochem. 1999; 73(1):70-78; Koeberle & Ball Neuroscience. 2002; 110(3):555-567; Bilak et al. Mol Cel. Neurosci. 1999; 13(5):326-336; Perez-Navarro et al. Neuroscience. 2000; 98(1):89-96; Rosenblad et al, Eur J Neurosci. 1999; 11 (5):1554-1566, the disclosures of which are herein incorporated by reference).
"It was found, however, that upon convection-enhanced delivery (CED) into rat brains, the distribution volume of neurturin and the related factor GDNF was limited (Hamilton et al., Exp Neurol. 2001; 168(1):155-161). In our own studies, we found that the bioavailability after subcutaneous and intravenous injection of neurturin is low, only about 10 percent of subcutaneously injected neurturin enter the circulation (see FIG. 1). It would, therefore, be highly desirable to provide a formulation form that enhance the bioavailability of neurturin.
"Heparin has been used extensively in medicine due to its anticoagulant activities. Inhibition of blood clotting by heparin occurs by binding and inhibition of the factor Xa protease and other serine proteases participating in the blood clotting cascade, and a minimal pentasaccharide required for factor Xa inhibition has been described (Wang et al., J Clin Invest. 2002; 110:127-136; Esko Lindahl J Clin Invest. 2001; 108(2)169-173; Weitz, J L, N Engl J Med. 1997; 337(10):688-698)).
"It is known that protein growth factors such as VEGF, bFGF, neurturin and the related protein GDNF bind to heparin (Lin et al J Neurochem. 1994; 63 (2):758-768; WO 97/08196; Kotzbauer et al. Nature. 1996; 384(6608):467-470; Hamilton et al., supra). Unfractionated Heparin consists of glycosaminoglycan polymer chains. These chains contain alternating residues of D-glucosamine and uronic acid (either glucuronic acid or iduronic acid), and have molecular weights up to about 30000 Dalton (Weitz et al., supra).
"Hamilton et al. have observed a significantly increased distribution volume upon CED of GDNF and neurturin together with heparin.
"For GDNF it has been demonstrated that heparin can enhance binding to its receptor GFRa1, and that heparin-bound GDNF is protected from proteolytic attack (Rickard et al, Glycobiology. 2003; 13(6):419-426).
"U.S. Pat. No. 5,849,689 discloses administration of hepatocyte growth factor (HGF) in combination with heparin, low molecular weight heparin and pentosan polysulphate. It was shown that plasma half-life of HGF was significantly enhanced by co-administering HGF and heparin, while coadministration of HGF with low molecular weight heparin led to only small increase in plasma half-life compared to administration of HGF alone.
"It was found by the present inventors that the bioavailability of neurturin is, however, only moderately increased by heparin, particularly after subcutaneous administration. Thus, the object of the present invention was to provide novel formulations of protein growth factors, particularly novel formulations of neurturin, which have significantly increased bioavailability."
Supplementing the background information on this patent application, NewsRx reporters also obtained the inventors' summary information for this patent: "The present invention relates to a pharmaceutical formulation comprising a protein growth factor such as neurturin as an active ingredient and a low molecular weight polyanionic polymer together with pharmaceutically acceptable carriers, diluents and/or adjuvants.
"In a further embodiment, the present invention relates to a method for administering a protein growth factor to a subject in need thereof, wherein a pharmaceutical formulation is administered comprising a protein growth factor as an active ingredient and a low molecular weight polyanionic polymer together with pharmaceutically acceptable carriers, diluents and/or adjuvants.
"In a preferred embodiment of the invention, the protein growth factor is a neurturin protein product.
"In another preferred embodiment of the invention, the polyanionic polymer is a low molecular weight heparin or a pentosan polysulphate (PPS).
"The formulations of the present invention are particularly suitable for preventing or treating pancreatic disorders, more particularly pancreatic autoimmune disorders, e.g. autoimmune diabetes such as type I diabetes or LADA but also type II diabetes.
"The formulations of the present invention are particularly suitable for preventing or treating neurodegenerative disorders, more particularly diabetic polyneuropathy."
For the URL and additional information on this patent application, see: Harder, Friedrich; Austen, Matthias. New Formulation for Increasing Bioavailability of Neurturin. U.S. Patent Serial Number 595706, filed August 27, 2012, and posted March 7, 2013. Patent URL: http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H… [http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H…]
Keywords for this news article include: Heparin, Therapy, Pancreas, Wellness, Immunology, Proinsulin, Legal Issues, Endocrinology, Gastroenterology, Peptide Hormones, Diabetes Mellitus, Metabolic Diseases, Autoimmune Diseases, Autoimmune Disorders, Endocrine System Diseases, DeveloGen Aktiengesellschaft, Glucose Metabolism Disorders.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
DeveloGen Aktiengesellschaft; Agency Reviews Patent Application Approval Request for "New Formulation for Increasing Bioavailability of Neurturin"
1532 words
22 March 2013
Health & Medicine Week
HAMW
1442
English
(c) Copyright 2013 Health & Medicine Week via NewsRx.com
2013 MAR 22 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- DeveloGen Aktiengesellschaft has been issued patent application serial number 595706, according to news reporting originating out of Washington, D.C., by NewsRx editors.
The patent's inventors are Harder, Friedrich (Wasserburg, DE); Austen, Matthias (Gottingen, DE).
This patent application was filed on August 27, 2012 and was cleared for further review on March 7, 2013.
From the background information supplied by the inventors, news correspondents obtained the following quote: "Pancreatic beta-cells secrete insulin in response to elevated blood glucose levels. Insulin amongst other hormones plays a key role in the regulation of the fuel metabolism. Insulin leads to the storage of glycogen and triglycerides and to the synthesis of proteins. The entry of glucose into muscles and adipose cells is stimulated by insulin. In patients who suffer from diabetes mellitus type I or LADA (latent autoimmune diabetes in adults, Pozzilli & Di Mario, 2001, Diabetes Care. 8:1460-1467) beta-cells are being destroyed due to autoimmune attack. The amount of insulin produced by the remaining pancreatic islet cells is too low, resulting in elevated blood glucose levels (hyperglycemia). In diabetes mellitus type II liver and muscle cells loose their ability to respond to normal blood insulin levels (insulin resistance). High blood glucose levels (and also high blood lipid levels) in turn lead to an impairment of beta-cell function and to an increase in beta-cell death. Interestingly the rate of beta-cell neogenesis and replication does not appear to increase in type II diabetics, thus causing a reduction in total beta-cell mass over time. Eventually the application of exogenous insulin becomes necessary in type II diabetics.
"In type I diabetics, where beta-cells are being destroyed by autoimmune attack, treatments have been devised which modulate the immune system and may be able to stop or strongly reduce islet destruction (Raz et al., 2001, Lancet 358: 1749-1753; Chatenoud et al., 2003, Nat Rev Immunol. 3: 123-132; Homann et al., Immunity. 2002, 3:403-415). However, due to the relatively slow regeneration of human beta-cells such treatments can be more successful if they are combined with treatments that can stimulate beta-cell regeneration.
"Diabetes is a very disabling disease, because today's common anti-diabetic drugs do not control blood sugar levels well enough to completely prevent the occurrence of high and low blood sugar levels. Frequently elevated blood sugar levels are toxic and cause long-term complications like for example nephropathy; retinopathy, neuropathy and peripheral vascular disease. Extensive loss of beta cells also leads to deregulation of glucagon secretion from pancreatic alpha cells which contributes to an increased risk of dangerous hypoglycemic episodes. There is also a host of related conditions, such as obesity, hypertension, heart disease and hyperlipidemia, for which persons with diabetes are substantially at risk.
"Apart from the impaired quality of life for the patients, the treatment of diabetes and its long term complications presents an enormous financial burden to our healthcare systems with rising tendency. Thus, for the treatment of diabetes mellitus type I and LADA, but also for the treatment of late stages of diabetes mellitus type II there is a strong need in the art to identify factors that induce regeneration of pancreatic insulin producing beta-cells. These factors could restore normal function of the endocrine pancreas once its function is impaired or event could prevent the development or progression of diabetes type I, LADA or diabetes type II.
"Neurturin is expressed in embryonic pancreas, and recombinant neurturin has been shown to stimulate the differentiation of mouse ES-cells into insulin producing cells. Moreover, transgenic mice with elevated neurturin levels in the pancreas have a substantially increased pancreatic beta-cell mass. Based on these findings, the use of neurturin for the treatment of pancreatic disorders such as diabetes has been proposed (see for example WO03/099318 and WO2005/051415, the disclosure of which is herein incorporated by reference).
"Neurturin had previously been proposed as a treatment for neurodegenerative diseases such as Parkinsons, Alzheimers and Huntington's disease, motor neuron disorders, spinal cord injuries or hearing disorders (WO 97/08196, WO 99/06064; Akerud et al. J Neurochem. 1999; 73(1):70-78; Koeberle & Ball Neuroscience. 2002; 110(3):555-567; Bilak et al. Mol Cel. Neurosci. 1999; 13(5):326-336; Perez-Navarro et al. Neuroscience. 2000; 98(1):89-96; Rosenblad et al, Eur J Neurosci. 1999; 11 (5):1554-1566, the disclosures of which are herein incorporated by reference).
"It was found, however, that upon convection-enhanced delivery (CED) into rat brains, the distribution volume of neurturin and the related factor GDNF was limited (Hamilton et al., Exp Neurol. 2001; 168(1):155-161). In our own studies, we found that the bioavailability after subcutaneous and intravenous injection of neurturin is low, only about 10 percent of subcutaneously injected neurturin enter the circulation (see FIG. 1). It would, therefore, be highly desirable to provide a formulation form that enhance the bioavailability of neurturin.
"Heparin has been used extensively in medicine due to its anticoagulant activities. Inhibition of blood clotting by heparin occurs by binding and inhibition of the factor Xa protease and other serine proteases participating in the blood clotting cascade, and a minimal pentasaccharide required for factor Xa inhibition has been described (Wang et al., J Clin Invest. 2002; 110:127-136; Esko Lindahl J Clin Invest. 2001; 108(2)169-173; Weitz, J L, N Engl J Med. 1997; 337(10):688-698)).
"It is known that protein growth factors such as VEGF, bFGF, neurturin and the related protein GDNF bind to heparin (Lin et al J Neurochem. 1994; 63 (2):758-768; WO 97/08196; Kotzbauer et al. Nature. 1996; 384(6608):467-470; Hamilton et al., supra). Unfractionated Heparin consists of glycosaminoglycan polymer chains. These chains contain alternating residues of D-glucosamine and uronic acid (either glucuronic acid or iduronic acid), and have molecular weights up to about 30000 Dalton (Weitz et al., supra).
"Hamilton et al. have observed a significantly increased distribution volume upon CED of GDNF and neurturin together with heparin.
"For GDNF it has been demonstrated that heparin can enhance binding to its receptor GFRa1, and that heparin-bound GDNF is protected from proteolytic attack (Rickard et al, Glycobiology. 2003; 13(6):419-426).
"U.S. Pat. No. 5,849,689 discloses administration of hepatocyte growth factor (HGF) in combination with heparin, low molecular weight heparin and pentosan polysulphate. It was shown that plasma half-life of HGF was significantly enhanced by co-administering HGF and heparin, while coadministration of HGF with low molecular weight heparin led to only small increase in plasma half-life compared to administration of HGF alone.
"It was found by the present inventors that the bioavailability of neurturin is, however, only moderately increased by heparin, particularly after subcutaneous administration. Thus, the object of the present invention was to provide novel formulations of protein growth factors, particularly novel formulations of neurturin, which have significantly increased bioavailability."
Supplementing the background information on this patent application, NewsRx reporters also obtained the inventors' summary information for this patent: "The present invention relates to a pharmaceutical formulation comprising a protein growth factor such as neurturin as an active ingredient and a low molecular weight polyanionic polymer together with pharmaceutically acceptable carriers, diluents and/or adjuvants.
"In a further embodiment, the present invention relates to a method for administering a protein growth factor to a subject in need thereof, wherein a pharmaceutical formulation is administered comprising a protein growth factor as an active ingredient and a low molecular weight polyanionic polymer together with pharmaceutically acceptable carriers, diluents and/or adjuvants.
"In a preferred embodiment of the invention, the protein growth factor is a neurturin protein product.
"In another preferred embodiment of the invention, the polyanionic polymer is a low molecular weight heparin or a pentosan polysulphate (PPS).
"The formulations of the present invention are particularly suitable for preventing or treating pancreatic disorders, more particularly pancreatic autoimmune disorders, e.g. autoimmune diabetes such as type I diabetes or LADA but also type II diabetes.
"The formulations of the present invention are particularly suitable for preventing or treating neurodegenerative disorders, more particularly diabetic polyneuropathy."
For the URL and additional information on this patent application, see: Harder, Friedrich; Austen, Matthias. New Formulation for Increasing Bioavailability of Neurturin. U.S. Patent Serial Number 595706, filed August 27, 2012, and posted March 7, 2013. Patent URL: http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H… [http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H…]
Keywords for this news article include: Heparin, Therapy, Pancreas, Wellness, Immunology, Proinsulin, Legal Issues, Endocrinology, Gastroenterology, Peptide Hormones, Diabetes Mellitus, Metabolic Diseases, Autoimmune Diseases, Autoimmune Disorders, Endocrine System Diseases, DeveloGen Aktiengesellschaft, Glucose Metabolism Disorders.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Antwort auf Beitrag Nr.: 44.283.520 von submersus am 21.03.13 19:09:31Habe die 30-seitige Analyse der DB vom 21.12.2012 vorliegen. Titel "Evolution but no revolution; initiating with Hold"
Aber ein Bier will ich nicht ;-)
Aber ein Bier will ich nicht ;-)
Antwort auf Beitrag Nr.: 44.283.638 von HerrLich81 am 21.03.13 19:39:23Nein, das ist nicht normal...das ist Absicht!
DB 2,60 Coba 4.10 - ergo, alles Quatsch!
Ich bleibe auf jeden Fall dabei...auf "etwas" längere Sicht ein klarer Kauf!
DB 2,60 Coba 4.10 - ergo, alles Quatsch!
Ich bleibe auf jeden Fall dabei...auf "etwas" längere Sicht ein klarer Kauf!
Ist schon klar, dass die ihre Analysen vor den Zahlen rausgeben. Kein Problem. Aber warum wird das Kursziel gesenkt?
Kursziele kann ich dann anheben oder reduzieren, wenn die Zahlen und der Ausblick draußen sind.
Aber vorher? Findest Du das normal?
Gruß
Kursziele kann ich dann anheben oder reduzieren, wenn die Zahlen und der Ausblick draußen sind.
Aber vorher? Findest Du das normal?
Gruß
Antwort auf Beitrag Nr.: 44.282.793 von evotecci am 21.03.13 16:56:34. . . Die letzte analyse der db ? Wer es findet bekommt ein bier !
Gruss
Gruss
Trading Spotlight
viileicht ist gut e zeit bei evotec vorbei,
Antwort auf Beitrag Nr.: 44.282.980 von the_hitman am 21.03.13 17:25:04Komisch, dass Du hierbei das wichtigste natürlich aussen vor lässt.
Der Vorstand darf derzeit aufgrund der kommenden Zahlen gar keine Aktien kaufen!!
Zumal, chip hat es auch erwähnt, WL hat schon sehr viele Aktien u. auch sicher keine verkauft.
Der Vorstand darf derzeit aufgrund der kommenden Zahlen gar keine Aktien kaufen!!
Zumal, chip hat es auch erwähnt, WL hat schon sehr viele Aktien u. auch sicher keine verkauft.
Zitat von HerrLich81: Ja ja die Banken. Man schaue sich nur das Datum der Analyse an. Kurz vor den Zahlen. Das sagt meiner Meinung nach alles.
Ich bleibe jedenfalls drin. Und das für lange lange Zeit.
Was sagt denn das Datum aus?
Ist doch das normalste der Welt, machen sehr viele Analysten bei fast allen Aktien auf der Welt so:
Vor den Zahlen kommt ein update der Einschätzung, dann kommt die Präsentation der Zahlen mit Ausblick. Danach gibts einen update der Analyse:
Erwartung getroffen.... enttäuscht.... überrascht mit dies und das....
Das Analysten vor den Zahlen Erwartungen in den Ring schmeissen ist wirklich das normalste der Welt. Das immer wieder behauptet wird, die hätten die Zahlen vorher bekommen auch. Nur warum liegen die Analos nach den Zahlen so häufig schief?
ich ärgere mich auch über den kurs über was ich mich aber noch viel mehr hier ärgere ist das bla bla rock bla.
wir sind hier halt nun mal nicht bei einer daimler sonder bei einem biotech und hat wl ein stück verkauft nein und er hat sicherlich besseren einblick als alle hier und hat auch mehr aktien als die meisten hier.
und bevor man hier über ihn mist schreibt sollte man ihm mal persönlich anschreiben.
wenn ich ihn anschreibe bin ich sogar überrascht wie schnell man eine antwort bekommt teilweise in minuten!
ich bin hier sicherlich überdurchschnittlich stark investiert und trotzdem überlege ich weiter aufzustocken da das kursniveau einfach zu verlockend ist.
und wenn man der piepeline noch 2-3 jahre zeit gibt sollte da eine ganz ordentliche rendite rauskommen!
schönen abend allen treuen evotec aktionären ;-)
chip
wir sind hier halt nun mal nicht bei einer daimler sonder bei einem biotech und hat wl ein stück verkauft nein und er hat sicherlich besseren einblick als alle hier und hat auch mehr aktien als die meisten hier.
und bevor man hier über ihn mist schreibt sollte man ihm mal persönlich anschreiben.
wenn ich ihn anschreibe bin ich sogar überrascht wie schnell man eine antwort bekommt teilweise in minuten!
ich bin hier sicherlich überdurchschnittlich stark investiert und trotzdem überlege ich weiter aufzustocken da das kursniveau einfach zu verlockend ist.
und wenn man der piepeline noch 2-3 jahre zeit gibt sollte da eine ganz ordentliche rendite rauskommen!
schönen abend allen treuen evotec aktionären ;-)
chip
Zitat von evotecci: Vorneweg, mir gefällt dieser Kurs auch nicht...finds zum Kotzen!!
Aber was Du da schreibst ist oft nicht zu begreifen!
Was soll Frau Hansen denn anderes schreiben???
Soll Evotec eine News rausgeben mit dem Wort laut"Sorry Leute bei uns ist alles iO, der Kursrückgang ist nicht gerechtfertigt"???
Die Shorties würden sich darüber totlachen u. ich als Aktionär würde mich über solch dummen Aktionismus seitens Evotec ärgern.
Nächte Woche kommen die Zahlen, mal sehen, ob das dann auch ein Thema sein wird.
Ich kann Eck64 bei diesem Thema nur zustimmen.....extrem abstrus was hier teilweise geschrieben wird!
Denke, EVO bzw. die Herren Vorstände könnten einiges tun !!
Wie wäre es denn mal mit einem kräftigen Aktieneinkauf der Herren
auf eigene Rechnung ?
So als vertrauensbildende Maßnahme !!
Durchsuchen
04:45 Uhr · inv3st.de · BayerAnzeige |
12.05.24 · wO Chartvergleich · Carl Zeiss Meditec |
11.05.24 · wO Chartvergleich · American Express |
10.05.24 · Sharedeals · Evotec |
09.05.24 · Sharedeals · Evotec |
09.05.24 · wallstreetONLINE Redaktion · Bayer |
09.05.24 · kapitalerhoehungen.de · Bayer |
08.05.24 · wallstreetONLINE Redaktion · Evotec |